News | May 30, 2025
Sudeep Pharma acquires Nutrition Supplies Services
This strategic move positions Sudeep Pharma to seamlessly integrate high-end premix capabilities with its mineral portfolio
This strategic move positions Sudeep Pharma to seamlessly integrate high-end premix capabilities with its mineral portfolio
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
Annual EBITDA margin expands by 170 basis points
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
The initiative was announced at World Hypertension Congress, Chennai
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
Subscribe To Our Newsletter & Stay Updated
